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Background: It is unclear if stress testing followed by targeted aspirin and statin therapy in intermediate risk persons is more cost-effective than 
no-test strategies.
Methods: Stress test results were incorporated into The CHD Policy Model by assuming higher CHD risk in test+ persons. Stress ECG with nuclear 
stress was assigned sensitivity 88%, specificity 70% and stress ECG alone sensitivity 68%, specificity 77% for identifying high risk persons. Testing 
all intermediate risk persons with intensification of statin and aspirin treatment in test+ persons was compared with current aspirin and statin use 
(base case) and to treatment of all intermediate risk persons. Twenty year costs, CHD events, and quality-adjusted life years (QALYs) were projected.
Results: Treatment targeted by stress ECG was more effective and less expensive than base case, but treatment of all patients without testing 
was the most effective strategy and relatively affordable (incremental cost-effectiveness ratio $16,700/QALY vs. stress ECG with 100% medication 
adherence.) Sensitivity analysis with varied adherence (Figure) found nuclear stress testing to be more effective only if testing + led to increased 
medication adherence (>80% vs. 40% in no-test treat all strategies).
Conclusions: Unless testing itself substantially boosts medication adherence, treating all intermediate risk persons with 
generic statins and aspirin is more cost-effective than targeting treatment to intermediate risk persons with + stress tests.
